Public reprimand for Pierre Fabre

Call rates and certification of meetings

Pierre Fabre has been publicly reprimanded by the Code of Practice Appeal Board for failing to provide complete and accurate information to the Panel (Case AUTH/2962/7/17).

In Case AUTH/2962/7/17 the Panel ruled breaches of the Code and on appeal the Appeal Board ruled a breach of Clause 2 in relation to briefing material for the Toviaz (fesoterodine) representatives.

The Appeal Board noted that the presentation provided by Pierre Fabre in response to the complaint was incomplete. Pierre Fabre was only able to provide
the correct version of the slides which contained seven additional slides after being advised of the omission by the complainant in his/her appeal. In the Appeal Board’s view, this omission was a serious matter. The Appeal Board queried the robustness of the company’s original investigation and response on this point. The Appeal Board noted Pierre Fabre’s submission that the responsible individual had since left the company. However, the Appeal Board noted and welcomed the fact that Pierre Fabre had taken significant and rapid action and had in place a comprehensive and timely action plan to make wholesale changes to address issues highlighted in this case. However, notwithstanding its comments the Appeal Board considered that it was essential that pharmaceutical companies provided complete and accurate information to the Panel.

Code of Practice Review 2018 May - Number 100